Continue on TOI App
Open App
OPEN APP

Covid-19: Vaccine availability will improve by July, says Niti Aayog’s Vinod Paul

Vaccine availability in India will significantly improve by July,... Read More
PUNE: Vaccine availability in India will significantly improve by July, with the ramping up of domestic production and arrival of foreign vaccines, a top official has said.

Tired of too many ads?go ad free now

Dr Vinod Paul, member of the NITI Aayog and chairman of the government’s empowered group on

Covid

management, said relaxation of norms will let the country fast-track greenlighting of foreign-made vaccines that have been granted emergency-use approvals in other countries.

He added that production of both Covaxin and Covishield is also being scaled up.

“We are expecting current production levels of Covaxin and Covishield to be scaled up, as has been committed by their manufacturers (Bharat Biotech and Serum Institute). We also expect Pfizer, Moderna and Johnson & Johnson to seek Indian licence as soon as possible," Dr Paul said.



Tired of too many ads?go ad free now
The Russian-made Sputnik-V vaccine is also likely to be available in India after May.

Some of these foreign-made vaccines need very low storage temperatures - from -25°C to -70°C. Dr Paul said, depending on approvals, some of these shots can be deployed in urban centres.

The

National Expert Group on Vaccine Administration

has recommended that vaccines for Covid-19, that have been developed and manufactured in foreign countries (and added to the WHO's emergency-use listing), may be granted approvals in India. These approvals will be accompanied by relevant checks.

Tired of too many ads?go ad free now


"The first 100 beneficiaries of these foreign vaccines will be assessed for a week for safety outcomes, before they are rolled out as part of the larger immunization programme in the country," Dr Paul said.

The addition of more vaccines to India's basket will let the government cover more age groups. "Better the availability, the more age groups we can cover. The government is looking to first cover the 45-plus group and then, depending on availability, expand the drive to cover others, which has been the demand of many states," he said.

Tired of too many ads?go ad free now
He added that while more Covishield doses are expected, the supply of Covaxin will see considerable improvement in the future following production approvals to public sector units.

Stay updated with the latest news on Times of India. Don't miss daily games like Crossword, Sudoku, and Mini Crossword.
Continue Reading
Follow Us On Social Media
end of article
More Trending Stories
Visual Stories
More Visual Stories
UP NEXT
Do Not Sell Or Share My Personal Information